KEYTRUDA Injection 20mg [PD-L1 positive unresectable advanced/recurrent non-small cell lung cancer]（キイトルーダ点滴静注20mg［PD-L1陽性の切除不能な進行・再発の非小細胞肺癌］）
|
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
|
|
Brand name :
|
KEYTRUDA Injection 20mg [PD-L1 positive unresectable advanced/recurrent non-small cell lung cancer]
|
|
Active ingredient:
|
Pembrolizumab (genetical recombination)
|
|
 |
Effects of this medicine
This medicine inhibits the binding of PD-1, a receptor on T cells (immune cells), to PD-L1 and PD-L2, substances produced by cancer cells, thereby enhancing T cell activation and suppressing tumor growth.
It is usually used to treat PD-L1-positive, unresectable, advanced/recurrent non-small-cell lung cancer.
|
Before using this medicine, be sure to tell your doctor and pharmacist
-
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have: autoimmune disorder or its history, interstitial pulmonary disease or its history.
-
If you are pregnant, possibly pregnant or breastfeeding.
-
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
|
Dosing schedule (How to take this medicine)
-
Your dosing schedule prescribed by your doctor is (( to be written by a healthcare professional))
-
In general, for adults, administer by intravenous infusion over 30 minutes once every 3 weeks.
-
Ask the doctor about the treatment span.
|
Precautions while taking this medicine
|
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include fatigue, diarrhea, fever, itching and malaise. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
-
fever, dry cough, breathing difficulty [interstitial lung disease]
-
vomiting, abdominal pain, diarrhea, muddy stool [colitis, severe diarrhea]
-
redness of the eye and eyelid, erosions of lips or mouth, rash, blister [muco-cutaneo-ocular syndrome, erythema multiform]
-
intensely itchy blister [pemphigoid]
-
paralyzed motion, numbness of limbs, numbness of fingertips, difficulty in walking [neurological disorder]
-
general malaise, yellowing of the white of eyes, itching [liver dysfunction, hepatitis]
-
sweating, palpitation, general malaise, intolerance to cold [disturbed thyroid function]
-
general malaise, blank feeling and loss of consciousness, blood pressure falling [pituitarism]
-
general malaise, decreased consciousness, hypotension [adrenal dysfunction]
-
general malaise, thirst, increased urine output, decreased consciousness [type 1 diabetes mellitus]
-
edema, headache, decreased urine output [renal disorder]
-
nausea, vomiting, severe gastric/abdominal pain, back pain [pancreatitis]
-
lassitude, muscle pain, breathing difficulty, reddish brown urine [myositis, rhabdomyolysis]
-
blepharoptosis, drooping of upper eye lid, double vision, muscle fatigue [myasthenia gravis]
-
fever, headache, decreased consciousness [encephalitis, meningitis]
-
respiratory distress, consciousness disorder, swelling of eyelids/lips/tongue [infusion reaction]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
|
|
